SRPT Stock Chart & Stats
$294.00
$0.00(0.00%)
At close: 4:00 PM EDT
$294.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$255.02 - $450.00
Previous CloseN/A
Volume0.00
Average Volume (3M)4.00
Market Cap
$28.86B
Enterprise Value$3.04K
Total Cash (Recent Filing)$653.19M
Total Debt (Recent Filing)$1.04B
Price to Earnings (P/E)25.3
Beta0.05
Next Earnings
Aug 05, 2026EPS Estimate
3.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.62
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.98
Price to Sales (P/S)1.03
P/FCF Ratio-7.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$399.82Price Target Upside35.99% Upside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sarepta Therapeutics News
SRPT FAQ
What was Sarepta Therapeutics Inc.’s price range in the past 12 months?
Sarepta Therapeutics Inc. lowest stock price was $255.02 and its highest was $450.00 in the past 12 months.
What is Sarepta Therapeutics Inc.’s market cap?
Sarepta Therapeutics Inc.’s market cap is $28.86B.
When is Sarepta Therapeutics Inc.’s upcoming earnings report date?
Sarepta Therapeutics Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 8 days.
How were Sarepta Therapeutics Inc.’s earnings last quarter?
Sarepta Therapeutics Inc. released its earnings results on May 06, 2026. The company reported $50.21 earnings per share for the quarter, beating the consensus estimate of $17.016 by $33.194.
Is Sarepta Therapeutics Inc. overvalued?
According to Wall Street analysts Sarepta Therapeutics Inc.’s price is currently Undervalued.
Does Sarepta Therapeutics Inc. pay dividends?
Sarepta Therapeutics Inc. does not currently pay dividends.
What is Sarepta Therapeutics Inc.’s EPS estimate?
Sarepta Therapeutics Inc.’s EPS estimate is 3.78.
How many shares outstanding does Sarepta Therapeutics Inc. have?
Currently, no data Available
What happened to Sarepta Therapeutics Inc.’s price movement after its last earnings report?
Sarepta Therapeutics Inc. reported an EPS of $50.21 in its last earnings report, beating expectations of $17.016. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sarepta Therapeutics Inc.?
Currently, no hedge funds are holding shares in MX:SRPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sarepta Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$399.82 (35.99% Upside)
$399.82 (35.99% Upside)
Blogger Sentiment
Bullish
MX:SRPT Sentiment 70%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.27%
Trailing 12-Months
Company Description
Sarepta Therapeutics Inc.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
SRPT Company Deck
SRPT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely constructive tone: Sarepta reported profitable Q1 results, strong gross margins, and a $748M cash balance while reiterating full-year guidance of $1.2B–$1.4B. The company highlighted meaningful clinical progress—notably robust early siRNA data (FSHD, DM1), encouraging EMBARK 3‑year and MRI evidence for Alevitus, regulatory progress with sNDA submissions, and commercialization initiatives (expanded sales force). Offsetting these positives were lower Alevitus product sales driving a modest YoY revenue decline (–2%), an information gap slowing demand recovery, short-term cash outflows tied to planned Arrowhead payments, and unresolved safety/regulatory uncertainty for non‑ambulatory Alevitus use that depends on small open‑label cohorts. Overall, the call emphasized stabilization and long‑term opportunity but signaled that commercial recovery for Alevitus will be gradual and that some clinical/regulatory risks remain.View all MX:SRPT earnings summariesSRPT Stock 12 Month Forecast
Average Price Target
$399.82
▲(35.99% Upside)